Status:
UNKNOWN
The Predictive Role of HPV Integration in HSIL and Cervical Cancer
Lead Sponsor:
Tongji Hospital
Conditions:
HPV Integration
Eligibility:
FEMALE
18-70 years
Brief Summary
The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervic...
Eligibility Criteria
Inclusion
- HPV-positive patients； Patients have completed HPV detection, TCT, and HPV integration detection before surgery or biopsy； Patients with priced diagnoses accepted treatment according to ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors； Patients who are voluntary participants in this research and cooperate to follow-up with subscribing informed consent.
Exclusion
- Patients who are not suitable for the trial； Patients existing other subtype malignancy tumors are still in treatment.
Key Trial Info
Start Date :
July 7 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05300243
Start Date
July 7 2020
End Date
June 1 2022
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China, 350000